SWOG clinical trial number
CTSU/C80701

Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

Closed
Phase
Abbreviated Title
Rando Ph II Everolimus vs Everolimus+Bev for Adv/Met Pancreatic Neuroendorine Tumors
Activated
03/01/2012
Closed
10/01/2012
Participants
CTSU

Research committees

Gastrointestinal Cancer

Treatment

Bevacizumab Everolimus

Publication Information Expand/Collapse

2022

Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)

M Kulke;F-S Ou;D Niedwiecki;L Heubner;P Kunz;H Kennecke;E Wolin;J Chan;E O'Reilly;J Meyerhardt;A Venook Endocrine-Related Cancer May 9;29(6):335-344

PMid: PMID35324465

2015

Randomized phase II study of everolimus alone (E) versus everolimus plus bevacizumab (E+B) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors, CALGB 80701

M Kulke;D Niedzwiecki;N Foster;B Fruth;H Kennecke;E Wolin;A Venook Journal of Clinical Oncology 33:5s (suppl; abstr 4005); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
83%
Open
Phase